Prenetics raises 2026 revenue guidance to $220 million-$230 million
PRE•Prenetics raised its 2026 revenue guidance to $220 million-$230 million and issued initial 2027 IM8 revenue guidance of at least $400 million, excluding upcoming product launches. IM8 reported second-quarter revenue of $45 million, up approximately 359% year over year, and July revenue of $20.9 million.
1. Updated revenue outlook
Prenetics raised its full-year 2026 revenue guidance to $220 million-$230 million. Its initial 2027 IM8 revenue guidance is $400 million or more, excluding upcoming product launches.
2. IM8 revenue figures
IM8's second-quarter 2026 revenue reached $45 million, up approximately 359% year over year. July revenue totaled $20.9 million, equivalent to an annualized revenue run rate of approximately $251 million. Both forecasts exclude Care Bears by IM8, whose gummy multivitamins are targeted for launch in the first half of 2027.
